---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-24-000078"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T07:23:45.506292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B

## Summary
- Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.
- Non-GAAP operating margin 15.2% (up 460 bps YoY); Non-GAAP EPS $0.32.
- FDA cleared Stelo, first OTC CGM for type 2 diabetes not on insulin; also cleared Direct-to-Watch for G7.
- Updated FY2024 revenue guidance to $4.20-4.35B (17-21% organic growth); reiterated Non-GAAP gross margin ~63-64% and operating margin ~20%.
- Cash $2.9B; revolving credit facility undrawn.

## SEC filing metadata
- accession: 0001093557-24-000078
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/0001093557-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/dxcm-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-24-000078
- JSON: https://secwatch.observer/filing/0001093557-24-000078.json
- Plain text: https://secwatch.observer/filing/0001093557-24-000078.txt

## Key facts
- Earnings Releases
  DEXCOM INC reported the quarter ended March 31, 2024 results: revenue $921.0 million, net income $146.4 million, or $0.36 per diluted share, EPS $0.36 per diluted share. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $921.0 million
  - Net income: $146.4 million, or $0.36 per diluted share
  - EPS: $0.36 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: • Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic 1 basis. • U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/0001093557-24-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.